Adjunct Clinical Professor, Department of Family and Community Medicine
Biosketch
Michael Klepser, PharmD, received his Doctor of Pharmacy from the University of Michigan College of Pharmacy in 1992. He completed a pharmacy practice residency at Detroit Receiving Hospital and University Health Center and a fellowship in Infectious Diseases at Hartford Hospital in Hartford, Connecticut. Dr. Klepser has been a Professor of Pharmacy at Ferris State University since 2001. Dr. Klepsers research interests include use of CLIA-waived point-of-care tests in community pharmacies and community-based antimicrobial stewardship. He has published extensively on these topics and has more than 130 peer-reviewed manuscripts to his credit. Dr. Klepser is a founder and content advisor for the Community Pharmacy-Based Point-of-Care Testing certificate program.
-
Education and Training
- Fellowship 1995, Infectious Diseases, Hartford Hospital
- Residency 1993, Detroit Recieving Hospital
- PharmD 1992, College of Pharmacy, University of Michigan-Ann Arbor
-
Research
- Infectious Diseases
-
Publications
Beuschel T., Gootee E., Jordan M., Sikkenga T., Klepser D.G., Holmquist H., de Voest A., Klepser M.E. Time and motion study of hepatitis C virus point-of-care testing in community pharmacies Journal of the American Pharmacists Association. 2023;63:435-439.
Klepser D.G., Klepser M.E., Peters P.J., Hoover K.W., Weidle P.J. Implementation and Evaluation of a Collaborative, Pharmacy-Based Hepatitis C and HIV Screening Program Preventing chronic disease. 2022;19:E83.
Klepser M., Koski R.R. Molecular point-of-care testing in the community pharmacy setting: current status and future prospects Expert Review of Molecular Diagnostics. 2022;22:923-936.
Mahoney M.V., Bhagat H., Christian R., Del Rio C., Hohmeier K.C., Klepser M.E., Pogue J.M. Pharmacists as important prescribers of coronavirus disease 2019 (COVID-19) antivirals Antimicrobial Stewardship and Healthcare Epidemiology. 2022;2
Kepczynski C.M., Genigeski J.A., Koski R.R., Bernknopf A.C., Konieczny A.M., Klepser M.E. A systematic review comparing at-home diagnostic tests for SARS-CoV-2: Key points for pharmacy practice, including regulatory information Journal of the American Pharmacists Association. 2021;61:666-677.e2.
Klepser D.G., Klepser N.S., Adams J.L., Adams A.J., Klepser M.E. The impact of the COVID-19 pandemic on addressing common barriers to pharmacy-based point-of-care testing Expert Review of Molecular Diagnostics. 2021;21:751-755.
Klepser N.S., Klepser D.G., Adams J.L., Adams A.J., Klepser M.E. Impact of COVID-19 on prevalence of community pharmacies as CLIA-Waived facilities Research in Social and Administrative Pharmacy. 2021;17:1574-1578.
Eric Nybo S., Sahr M., Young M., Axford K., Sohn M., Lyons M., Klepser M. Design of a large-scale escape room for first-year pharmacy student orientation Currents in Pharmacy Teaching and Learning. 2020;12:1340-1347.
Herbin S.R., Klepser D.G., Klepser M.E. Pharmacy-based infectious disease management programs incorporating CLIA-waived point-of-care tests Journal of Clinical Microbiology. 2020;58
Nybo S.E., Klepser S.A., Klepser M. Design of a disaster preparedness escape room for first and second-year pharmacy students Currents in Pharmacy Teaching and Learning. 2020;12:716-723.
Sohn M., Chung D., Winterholler E., Hammershaimb B., Leist C., Kucera M., Trombly M., Tracey J., Dregansky G., Schauer M., Rauch H., Woodwyk A., VanLoo D., Warner A., Klepser M.E. Assessment of antibiotic use and concordance with practice guidelines within 3 diverse ambulatory clinic systems Journal of the American Pharmacists Association. 2020;60:930-936.e10.
Klepser D.G., Klepser M.E., Murry J.S., Borden H., Olsen K. Evaluation of a community pharmacy–based influenza and group A streptococcal pharyngitis disease management program using polymerase chain reaction point-of-care testing Journal of the American Pharmacists Association. 2019;59:872-879.
Adams A.J., Dering-Anderson A., Klepser M.E., Klepser D. The roles of pharmacy schools in bridging the gap between law and practice American Journal of Pharmaceutical Education. 2018;82(4):297-299.
Bacci J.L., Klepser D., Tilley H., Smith J.K., Klepser M.E. Community pharmacy-based point-of-care testing: A case study of pharmacist-physician collaborative working relationships Research in Social and Administrative Pharmacy. 2018;14(1):112-115.
Blanchette L., Gauthier T., Heil E., Klepser M., Kelly K.M., Nailor M., Wei W., Suda K. The essential role of pharmacists in antibiotic stewardship in outpatient care: An official position statement of the Society of Infectious Diseases Pharmacists Journal of the American Pharmacists Association. 2018;58:481-484.
Bright D., Klepser M., Murry L., Klepser D. Pharmacist-Provided Pharmacogenetic Point-of-Care Testing Consultation Service: A Time and Motion Study Journal of Pharmacy Technology. 2018;34:139-143.
Corn C.E., Klepser D.G., Dering-Anderson A.M., Brown T.G., Klepser M.E., Smith J.K. Observation of a Pharmacist-Conducted Group A Streptococcal Pharyngitis Point-of-Care Test: A Time and Motion Study Journal of Pharmacy Practice. 2018;31(3):284-291.
Klepser D.G., Klepser M.E. Point-of-care testing in the pharmacy: how is the field evolving? Expert Review of Molecular Diagnostics. 2018;18(1):5-6.
Klepser D.G., Klepser M.E., Smith J.K., Dering-Anderson A.M., Nelson M., Pohren L.E. Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting Research in Social and Administrative Pharmacy. 2018;14(4):356-359.
Klepser M.E., Adams A.J. Pharmacy-based management of influenza: lessons learned from research International Journal of Pharmacy Practice. 2018;26:573-578.
Dobson E.L., Klepser M.E., Pogue J.M., Labreche M.J., Adams A.J., Gauthier T.P., Turner R.B., Su C.P., Jacobs D.M., Suda K.J. Outpatient antibiotic stewardship: Interventions and opportunities Journal of the American Pharmacists Association. 2017;57(4):464-473.
Goza M., Kulwicki B., Akers J.M., Klepser M.E. Syphilis Screening: A Review of the Syphilis Health Check Rapid Immunochromatographic Test Journal of Pharmacy Technology. 2017;33(2):53-59.
Gubbins P.O., Klepser M.E., Adams A.J., Jacobs D.M., Percival K.M., Tallman G.B. Potential for Pharmacy-Public Health Collaborations Using Pharmacy-Based Point-of-Care Testing Services for Infectious Diseases Journal of Public Health Management and Practice. 2017;23(6):593-600.
Klepser M.E., Dobson E.L., Pogue J.M., Labreche M., Adams A.J., Gauthier T.P., Turner R.B., Su C.P., Jacobs D.M., Suda K.J. A call to action for outpatient antibiotic stewardship Journal of the American Pharmacists Association. 2017;57(4):457-463.
Koski R., Klepser M. A systematic review of rapid diagnostic tests for influenza: considerations for the community pharmacist Journal of the American Pharmacists Association. 2017;57(1):13-19.
Adams A.J., Klepser M.E., Klepser D. An update on community pharmacies as CLIA-waived facilities Research in Social and Administrative Pharmacy. 2016;12(4):666-667.
Gronowski A., Adams A., Ball C., Gaydos C., Klepser M. Pharmacists in the laboratory space: Friends or foes? Clinical Chemistry. 2016;62(5):679-683.
Klepser D.G., Klepser M.E., Dering-Anderson A.M., Morse J.A., Smith J.K., Klepser S.A. Community pharmacistephysician collaborative streptococcal pharyngitis management program Journal of the American Pharmacists Association. 2016;56(3):323-329.e1.
Klepser M., Adams A.J., Klepser D. Clinical service implementation in the face of initial regulatory uncertainty Journal of the American Pharmacists Association. 2016;56(5):492.
Klepser M.E., Adams A.J., Srnis P., Mazzucco M., Klepser D. U.S. community pharmacies as CLIA-waived facilities: Prevalence, dispersion, and impact on patient access to testing Research in Social and Administrative Pharmacy. 2016;12(4):614-621.
Klepser M.E., Klepser D.G., Dering-Anderson A.M., Morse J.A., Smith J.K., Klepser S.A. Effectiveness of a pharmacist-physician collaborative program to manage influenza-like illness Journal of the American Pharmacists Association. 2016;56(1):14-21.
Weber N.C., Klepser M.E., Akers J.M., Klepser D.G., Adams A.J. Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States Expert Review of Molecular Diagnostics. 2016;16(2):253-264.
Akinwale T.P., Adams A.J., Dering-Anderson A.M., Klepser M.E. Pharmacy-based point-of-care testing for infectious diseases: Considerations for the pharmacy curriculum Currents in Pharmacy Teaching and Learning. 2015;7(1):131-136.
Chopp S., Vanderwall R., Hult A., Klepser M. Simeprevir and sofosbuvir for treatment of hepatitis C infection American Journal of Health-System Pharmacy. 2015;72(17):1445-1455.
D'Angelo R.G., Klepser M., Woodfield R., Patel H. Hepatitis C virus screening: A review of the OraQuick hepatitis C virus rapid antibody test Journal of Pharmacy Technology. 2015;31(1):13-19.
Darin K.M., Klepser M.E., Klepser D.E., Klepser S.A., Reeves A., Young M., Scarsi K.K. Pharmacist-provided rapid HIV testing in two community pharmacies Journal of the American Pharmacists Association. 2015;55(1):81-88.
Darin K.M., Scarsi K.K., Klepser D.G., Klepser S.A., Reeves A., Young M., Klepser M.E. Consumer interest in community pharmacy HIV screening services Journal of the American Pharmacists Association. 2015;55(1):67-72.
Daunais D., Klepser M., Ogrin B. Assessment of pharmacy students' and licensed pharmacists' perceived knowledge, application, and interpretation regarding rapid diagnostic tests (RDTs) for infectious diseases Currents in Pharmacy Teaching and Learning. 2015;7(1):100-105.
Huang V., Klepser M.E., Gubbins P.O., Bergman S.J., Chahine E.B., Halilovic J., Hidayat L.K., Matthias K.R., Tesh L.D. Quantification of curricular content devoted to point-of-care testing for infectious diseases in schools and colleges of pharmacy in the United States Pharmacy Education. 2015;15(1):1-6.
Klepser D.G., Corn C.E., Schmidt M., Dering-Anderson A.M., Klepser M.E. Health care resource utilization and costs for influenza-like illness among midwestern health plan members Journal of Managed Care Pharmacy. 2015;21(7):568-573.
Klepser M., Adams A., Klepser D. Antimicrobial stewardship in outpatient settings: leveraging innovative physician-pharmacist collaborations to reduce antibiotic resistance Health security. 2015;13(3):166-173.
Dering-Anderson A., Gubbins P., Klepser D., Klepser M. To the Editor American Journal of Pharmaceutical Education. 2014;78(2)
Gubbins P.O., Klepser M.E., Dering-Anderson A.M., Bauer K.A., Darin K.M., Klepser S., Matthias K.R., Scarsi K. Point-of-care testing for infectious diseases: Opportunities, barriers, and considerations in community pharmacy Journal of the American Pharmacists Association. 2014;54(2):163-171.
Klepser M. Socioeconomic impact of seasonal (epidemic) influenza and the role of over-the-counter medicines Drugs. 2014;74(13):1467-1479.
Klepser D., Bisanz S., Klepser M. Cost-effectiveness of pharmacist-provided treatment of adult pharyngitis American Journal of Managed Care. 2012;18(4)
Klepser M. Pharmacological and host considerations in the selection of dose and duration of azole therapy for adult patients Current Fungal Infection Reports. 2012;6(2):127-132.
VanLangen K.M., Engle E., Hagerman J.K., Klepser M.E. Evaluation of student pharmacists' knowledge on influenza Currents in Pharmacy Teaching and Learning. 2012;4(1):46-51.
Freed S.L., Valente C.A., Hagerman J.K., Klepser D.G., Klepser M.E. Assessment of the curricular content devoted to the application and interpretation of rapid diagnostic tests in colleges of pharmacy in the United States Pharmacy Education. 2011;11(1):205-208.
Klepser M. Optimizing amphotericin B therapy for cryptococcal meningitis Current Fungal Infection Reports. 2011;5(2):57-58.
Klepser M. The value of amphotericin B in the treatment of invasive fungal infections Journal of Critical Care. 2011;26(2):225.e1-225.e10.
Klepser M. Safety and efficacy data for high-dose caspofungin Current Fungal Infection Reports. 2010;4(2):59-61.
Le J., Ashley E.D., Neuhauser M.M., Brown J., Gentry C., Klepser M.E., Marr A., Schiller D., Schwiesow J.N., Tice S., VandenBussche H.L., Wood G.C. Consensus summary of aerosolized antimicrobial agents: Application of guideline criteria insights from the society of infectious diseases pharmacists Pharmacotherapy. 2010;30(6):562-584.
Ruiz A.D., Frei C.R., Barner J.C., Carson J.J., Oramasionwu C.U., Ruiz J.L., Daniels K., Mohr J.F., Klepser M.E. Influenza vaccination rates among pharmacists Journal of the American Pharmacists Association. 2010;50(4):517-522.
Zoller E., Valente C., Baker K., Klepser M. Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections Drug Design, Development and Therapy. 2010;4:299-311.
Ernst E.J., Klepser M.E., Bosso J.A., Rybak M.J., Hermsen E.D., Segarra-Newnham M., Drew R.H. Recommendations for Training and Certification for Pharmacists Practicing, Mentoring, and Educating in Infectious Diseases Pharmacotherapy Joint Opinion of the Society of Infectious Diseases Pharmacists and the Infectious Diseases Practice and Research Network of the American College of Clinical Pharmacy Pharmacotherapy. 2009;29(4):482-488.
Frei C.R., Oramasionwu C.U., Mohr J., Klepser M., Barner J.C. Vaccination adherence and perceptions among infectious diseases pharmacists American Journal of Health-System Pharmacy. 2008;65(16):1500-1501.
Klepser M. Seasonal and pandemic influenza: Preparing pharmacists for the frontline Journal of the American Pharmacists Association. 2008;48(2):312-314.
Hagerman J., Knechtel S., Klepser M. Doripenem: A new extended-spectrum carbapenem antibiotic Formulary. 2007;42(12)
Hagerman J., Knechtel S., Klepser M. Tobramycin solution for inhalation in cystic fibrosis patients: A review of the literature Expert Opinion on Pharmacotherapy. 2007;8(4):467-475.
Knechtel S., Jacobs C., Klepser M. Telavancin: A novel lipoglycopeptide antibiotic with dual mechanisms of action Formulary. 2007;42(9):545-557.
Knechtel S.A., Klepser M.E. Safety of aerosolized amphotericin B Expert Opinion on Drug Safety. 2007;6(5):523-532.
Raguckas S.E., VandenBussche H.L., Jacobs C., Klepser M.E. Pertussis resurgence: Diagnosis, treatment, prevention, and beyond Pharmacotherapy. 2007;27(1):41-52.
Blostica T., Klepser M. Dalbavancin: A novel long-acting lipoglycopeptide antibiotic Formulary. 2006;41(2):59-73.
Hagerman J.K., Hancock K., Klepser M.E. Aerosolised antibiotics: A critical appraisal of their use Expert Opinion on Drug Delivery. 2006;3(1):71-86.
Klepser M. Candida resistance and its clinical relevance Pharmacotherapy. 2006;26(6 II)
Staat D., Klepser M. International adoption: Issues in infectious diseases Pharmacotherapy. 2006;26(9 I):1207-1220.
Lewis R., Wiederhold N., Klepser M. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrobial Agents and Chemotherapy. 2005;49(3):945-951.
VandenBussche H.L., Klepser M.E. Single daily tobramycin dosing in cystic fibrosis: Is it better for the patients or the bugs? Lancet. 2005;365(9459):547-548.
Klepser M. Role of nebulized antibiotics for the treatment of respiratory infections Current Opinion in Infectious Diseases. 2004;17(2):109-112.
Shah N., Reddy P., Paladino J., McKinnon P., Klepser M., Pashos C. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: An economic model Current Medical Research and Opinion. 2004;20(6):779-790.
Hoffman H., Klepser M., Ernst E., Petzold C., Sa'adah L., Doern G. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model Antimicrobial Agents and Chemotherapy. 2003;47(2):739-746.
Keele D., Crank C., Ernst E., Klepser M. Evaluation of amphotericin B and voriconazole in combination against fluconazole susceptible and resistant Candida isolates using time-kill methodology Journal of Infectious Disease Pharmacotherapy. 2003;6(1):49-63.
Klepser M.E., Klepser D.G., Ernst E.J., Brooks J., Diekema D.J., Mozaffari E., Hendrickson J., Doern G.V. Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae Pharmacotherapy. 2003;23(3):349-359.
Nicolau D., Klepser M. The Bacterial Revolt: What Can Be Done about Antibiotic-Resistant Pneumococci? Journal of Infectious Disease Pharmacotherapy. 2003;6(3):69-83.
Pawlitz D., Young M., Klepser M. Micafungin: A new echinocandin antifungal Formulary. 2003;38(6):354-367.
Viljoen A., Van Vuuren S., Ernst E., Klepser M., Demirci B., Başer H., Van Wyk B.E. Osmitopsis asteriscoides (Asteraceae)-the antimicrobial activity and essential oil composition of a Cape-Dutch remedy Journal of Ethnopharmacology. 2003;88(2-3):137-143.
Ernst E., Klepser M., Petzold C., Doern G. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection Pharmacotherapy. 2002;22(4):463-470.
Ernst E., Roling E., Petzold C., Keele D., Klepser M. In vitro activity of micafungin (FK-463) against Candida spp.: Microdilution, time-kill, and postantifungal-effect studies Antimicrobial Agents and Chemotherapy. 2002;46(12):3846-3853.
Ernst E., Yodoi K., Roling E., Klepser M. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, etest, and time-kill methods Antimicrobial Agents and Chemotherapy. 2002;46(2):578-581.
Flume P., Klepser M.E. The rationale for aerosolized antibiotics Pharmacotherapy. 2002;22(3 I)
Huffman A., Klepser D.M.E., Keele D.J., Roling E. Susceptibility of opportunistic bacteria and yeasts to the volatile oils of Artemisia afra, Lippia javanica, Lippia scaberrima, Myrothamnus flabellifolius and Osmitopsis asteriscoides Journal of Infectious Disease Pharmacotherapy. 2002;5:43-50.
Klepser M. Amphotericin B in lung transplant recipients Annals of Pharmacotherapy. 2002;36(1):167-169.
Klepser M. Novel Approaches for the Assessment of Costs Associated with Infectious Diseases: Introduction Pharmacotherapy. 2002;22(2 II)
Klepser M., Ernst E. Aminoglycosides and other antibiotics Pharmacokinetics in Drug Discovery and Development. 2002:127-137.
Klepser M.E., Klepser D.G. The dynamics of health care resource utilization Pharmacotherapy. 2002;22(2 II)
Lewis R.E., Diekema D.J., Messer S.A., Pfaller M.A., Klepser M.E. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species Journal of Antimicrobial Chemotherapy. 2002;49(2):345-351.
Roling E., Klepser M., Wasson A., Lewis R., Ernst E., Pfaller M. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods Diagnostic Microbiology and Infectious Disease. 2002;43(1):13-17.
Viljoen A.M., Klepser M.E., Ernst E.J., Keele D., Roling E., Van Vuuren S., Demirci B., Başer K., Van Wyk B.E. The composition and antimicrobial activity of the essential oil of the resurrection plant Myrothamnus flabellifolius South African Journal of Botany. 2002;68(1):100-105.
Hoffman H., Ernst E., Redford T., Klepser M. Effect of CpG DNA oligodeoxynucleotides and echinacea on the fungicidal activity of amphotericin B in a disseminated murine candidal infection model Journal of Infectious Disease Pharmacotherapy. 2001;4(4):55-66.
Hoffman H., Ernst E.J., Klepser M.E. A review of itraconazole spectrum of activity and dosage formulations Journal of Infectious Disease Pharmacotherapy. 2001;5(1):1-26.
Keele D., DeLallo V., Lewis R., Ernst E., Klepser M. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology Diagnostic Microbiology and Infectious Disease. 2001;41(3):121-126.
Klepser M. Pharmacotherapy: Introduction Pharmacotherapy. 2001;21(8 SUPPL. 2)
Klepser M., Ernst E., Petzold C., Rhomberg P., Doern G. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model Antimicrobial Agents and Chemotherapy. 2001;45(3):673-678.
Klepser M.E. Antifungal resistance among Candida species Pharmacotherapy. 2001;21(8 SUPPL. 2)
Klepser M.E., Lewis R.E., Ernst E.J., Rosemarie Petzold C., Bailey E.M., Burgess D.S., Carver P., Lacy M.K., Mercier R.C., Nicolau D.P., Zhanel G.G., Pfaller M.A. Multi-center evaluation of antifungal time-kill methods Journal of Infectious Disease Pharmacotherapy. 2001;5(2):29-41.
Ernst E., Klepser M., Pfaller M. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans Antimicrobial Agents and Chemotherapy. 2000;44(4):1108-1111.
Ernst E.J., Klepser M.E., Klepser T.B., Nightingale C.H., Hunsicker L.G. Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers Pharmacotherapy. 2000;20(6 I):657-661.
Gunderson S., Hoffman H., Ernst E., Pfaller M., Klepser M. In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect Antimicrobial Agents and Chemotherapy. 2000;44(10):2887-2890.
Hoffman H., Ernst E., Klepser M. Novel triazole antifungal agents Expert Opinion on Investigational Drugs. 2000;9(3):593-605.
Klepser M., Malone D., Lewis R., Ernst E., Pfaller M. Evaluation of voriconazole pharmacodynamics using time-kill methodology Antimicrobial Agents and Chemotherapy. 2000;44(7):1917-1920.
Klepser T., Doucette W., Horton M., Buys L., Ernst M., Ford J., Hoehns J., Kautzman H., Logemann C., Swegle J., Ritho M., Klepser M. Assessment of patients' perceptions and beliefs regarding herbal therapies Pharmacotherapy. 2000;20(1 I):83-87.
Lewis R., Klepser M., Ernst E., Snabes M., Jones R. Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection Diagnostic Microbiology and Infectious Disease. 2000;37(1):51-55.
Lewis R., Klepser M., Pfaller M. In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods Diagnostic Microbiology and Infectious Disease. 2000;36(2):101-105.
Appelbaum P.C., Klepser M.E. Role of the newer fluoroquinolones against penicillin-resistant Streptococcus pneumoniae Infectious Diseases in Clinical Practice. 1999;8(8):374-382.
Ernst E., Klepser M., Ernst M., Messer S., Pfaller M. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods Diagnostic Microbiology and Infectious Disease. 1999;33(2):75-80.
Klepser M. Overview of the in vitro activity of the newer fluoroquinolones Journal of Infectious Disease Pharmacotherapy. 1999;4(2):1-12.
Klepser T.B., Klepser M.E. Unsafe and potentially safe herbal therapies American Journal of Health-System Pharmacy. 1999;56(2):125-138.
Lewis R.E., Klepser M.E. The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy American Journal of Health-System Pharmacy. 1999;56(6):525-536.
Lewis R.E., Klepser M.E., Ernst E.J., Lund B.C., Biedenbach D.J., Jones R.N. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection Antimicrobial Agents and Chemotherapy. 1999;43(8):2005-2009.
Lewis R.E., Klepser M.E., Pfaller M.A. Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis Journal of Infectious Disease Pharmacotherapy. 1999;3(4):61-83.
Ernst E., Klepser M., Pfaller M. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: Effect of concentration and exposure time Diagnostic Microbiology and Infectious Disease. 1998;32(3):205-210.
Klepser M., Lewis R., Pfaller M. Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options Annals of Pharmacotherapy. 1998;32(12):1353-1361.
Klepser M., Patel K., Nicolau D., Quintiliani R., Nightingale C. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis Pharmacotherapy. 1998;18(5):1069-1074.
Klepser M.E., Ernst E.J., Ernst M.E., Messer S.A., Pfaller M.A. Evaluation of endpoints for antifungal susceptibility determinations with LY303366 Antimicrobial Agents and Chemotherapy. 1998;42(6):1387-1391.
Klepser M.E., Ernst E.J., Lewis R.E., Ernst M.E., Pfaller M.A. Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods Antimicrobial Agents and Chemotherapy. 1998;42(5):1207-1212.
Klepser M.E., Pfaller M.A. Variation in electrophoretic karyotype and antifungal susceptibility of clinical isolates of Cryptococcus neoformans at a university-affiliated teaching hospital from 1987 to 1994 Journal of Clinical Microbiology. 1998;36(12):3653-3656.
Klepser M.E., Wolfe E.J., Pfaller M.A. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans Journal of Antimicrobial Chemotherapy. 1998;41(3):397-401.
Lewis R., Klepser M. Update on clindamycin: New pharmacokinetic and pharmacodynamic data Infections in Medicine. 1998;15(10):726-731.
Lewis R., Klepser M., Pfaller M. Update on clinical antifungal susceptibility testing for Candida species Pharmacotherapy. 1998;18(3):509-515.
Lewis R.E., Lund B.C., Klepser M.E., Ernst E.J., Pfaller M.A. Assessment of antifungal activities of fluconazole and amphotericin b administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model Antimicrobial Agents and Chemotherapy. 1998;42(6):1382-1386.
Lund B.C., Ernst E.J., Klepser M.E. Strategies in the treatment of penicillin-resistant Streptococcus pneumoniae American Journal of Health-System Pharmacy. 1998;55(19):1987-1994.
Ernst M., Klepser M., Fouts M., Marangos M. Tetanus: Pathophysiology and management Annals of Pharmacotherapy. 1997;31(12):1507-1513.
Ernst M.E., Ernst E.J., Klepser M.E. Levofloxacin and trovafloxacin: The next generation of fluoroquinolones? American Journal of Health-System Pharmacy. 1997;54(22):2569-2584.
Hitt C.M., Klepser M.E., Nightingale C.H., Quintiliani R., Nicolau D.P. Pharmacoeconomic impact of once-daily aminoglycoside administration Pharmacotherapy. 1997;17(4):810-814.
Klepser M., Ernst E., Ernst M., Pfaller M. Growth medium effect on the antifungal activity of LY 303366 Diagnostic Microbiology and Infectious Disease. 1997;29(4):227-231.
Klepser M., Ernst E., Pfaller M. Update on antifungal resistance Trends in Microbiology. 1997;5(9):372-375.
Klepser M., Klepser T. Drug treatment of HIV-related opportunistic infections Drugs. 1997;53(1):40-73.
Klepser M.E., Marangos M.N., Zhu Z., Nicolau D.P., Quintiliani R., Nightingale C.H. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. 1997;41(2):435-439.
Klepser M.E., Nicolau D.P., Quintiliani R., Nightingale C.H. Bactericidal activity of low-dose clindamycin administered at 8- and 12- hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis Antimicrobial Agents and Chemotherapy. 1997;41(3):630-635.
Klepser M.E., Wolfe E.J., Jones R.N., Nightingale C.H., Pfaller M.A. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans Antimicrobial Agents and Chemotherapy. 1997;41(6):1392-1395.
Marangos N., Zhu Z., Nicolau D., Klepser M., Nightingale C. Disposition of ofloxacin in female New Zealand White rabbits Journal of Veterinary Pharmacology and Therapeutics. 1997;20(1):17-20.
Nicolau D.P., Banevicius M.A., Marangos M.N., Klepser M.E., Quintiliani R., Nightingale C.H. Influence of adjunct azithromycin on the mortality of experimental Pseudomonas aeruginosa sepsis International Journal of Antimicrobial Agents. 1997;8(4):239-241.
Ernst M., Klepser M., Wolfe E., Pfaller M. Antifungal dynamics of LY 303366, an investigational Echinocandin B analog, against Candida ssp. Diagnostic Microbiology and Infectious Disease. 1996;26(3-4):125-131.
Klepser M.E., Banevicius M.A., Quintiliani R., Nightingale C.H. Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods Antimicrobial Agents and Chemotherapy. 1996;40(8):1941-1944.
Klepser M.E., Zhu Z., Nicolau D.P., Banevicius M.A., Belliveau P.P., Ross J.W., Broisman L., Quintiliani R., Nightingale C.H. Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS Pharmacotherapy. 1996;16(4):656-662.
Klepser M., Marangos M., Patel K., Nicolau D., Quintiliani R., Nightingale C. Clinical Pharmacokinetics of Newer Cephalosporins Clinical Pharmacokinetics. 1995;28(5):361-384.
Klepser M., Patel K., Nicolau D., Quintiliani R., Nightingale C. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. 1995;39(11):2503-2510.
Klepser M., Quintiliani R., Nightingale C. Clinical experience with fleroxacin Drugs of Today. 1995;31(6):407-418.
Klepser M., Quintiliani R., Nightingale C. The use of zidovudine to prevent perinatal transmission of HIV Connecticut Medicine. 1995;59(6):343-345.
Patel K.B., Nicolau D.P., Klepser M.E., Marangos M.N., Hitt C.M., Nightingale C.H. Focus on fleroxacin: A new once daily fluoroquinolone antibiotic Formulary. 1995;30(5):261-267.
Klepser M., Herbert J. Evaluation of a systematic warfarin-dosing protocol P and T. 1994;19(9)
Klepser M., Quintiliani R., Nightingale C. Treatment of uncomplicated infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae Connecticut Medicine. 1994;58(8):489-494.
Klepser M. Sumatriptan: A novel therapy for the management of acute migraine Connecticut Medicine. 1993;57(11):747-750.
-
Presentations
- Outcomes From Outpatient Treatment of COVID-19 With Monoclonal Antibody Therapy: A Statewide Survey. Root B, Foshee R, Fales W, Cole S, Klepser M, Addis V, Alfred A, Christensen L, Dempsey B, Doan T, Gierka J, Gray M, Hebojiva E, Schmitt C, Shoemaker G, Ziccarello J, 38th Annual Kalamazoo Community Medical and Health Sciences Virtual Research Day, Kalamazoo, Michigan, 04/2021